FeirenSangza (Talk | contribs) |
|||
Line 1: | Line 1: | ||
− | {{Shenzhen_SFLS}} | + | {{Shenzhen_SFLS/Navigation}} {{Shenzhen_SFLS/Normal}} |
<html> | <html> | ||
+ | <head> | ||
+ | <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> | ||
+ | <title>Team:Shenzhen SFLS/Parts - 2017.igem.org</title> | ||
+ | <!-- Animate.css --> | ||
+ | <link rel="stylesheet" href="https://2017.igem.org/Template:Shenzhen_SFLS/css/animate?action=raw&ctype=text/css" type="text/css"> | ||
+ | <link href="https://2017.igem.org/Template:Shenzhen_SFLS/css/bootstrap?action=raw&ctype=text/css" rel="stylesheet" / type="text/css"> | ||
+ | <link href="https://2017.igem.org/Template:Shenzhen_SFLS/css/style?action=raw&ctype=text/css" rel="stylesheet" / type="text/css"> | ||
+ | <script src="https://2017.igem.org/Template:Shenzhen_SFLS/js/jquery?action=raw&ctype=text/javascript" type="text/javascript"></script> | ||
+ | <script src="https://2017.igem.org/Template:Shenzhen_SFLS/js/common?action=raw&ctype=text/javascript"></script> | ||
+ | <link href="https://2017.igem.org/Template:Shenzhen_SFLS/css/christmas?action=raw&ctype=text/css" rel="stylesheet" type="text/css" /> | ||
+ | <!-- Main --> | ||
+ | <script src="https://2017.igem.org/Template:Shenzhen_SFLS/js/main?action=raw&ctype=text/javascript"></script> | ||
+ | <style type="text/css"> | ||
+ | #table | ||
+ | { | ||
+ | width:100%; | ||
+ | border-collapse: separate; | ||
+ | border-spacing: 5px 0px; | ||
+ | } | ||
− | + | #table td, #table th | |
+ | { | ||
+ | font-size:14px; | ||
− | + | padding:3px 7px 2px 7px; | |
+ | text-align:center; | ||
+ | } | ||
+ | #table th | ||
+ | { | ||
+ | font-family: Montserrat-Light; | ||
+ | font-size:16px; | ||
+ | padding-top:12px; | ||
+ | padding-bottom:12px; | ||
+ | background-color: #FFAF00; | ||
+ | color:#ffffff; | ||
+ | border-radius: 6px; | ||
+ | } | ||
+ | #table td | ||
+ | { | ||
− | + | padding-top:15px; | |
+ | padding-bottom:15px; | ||
+ | background-color: #ffffff; | ||
+ | } | ||
+ | </style> | ||
+ | </head> | ||
+ | <body> | ||
− | <div class=" | + | <div class="img_head_bar container text-center"> |
− | <div class=" | + | <div class="display-t"> |
− | < | + | <div class="display-tc"> |
− | + | <h1>Parts</h1> | |
− | </div> | + | </div> |
− | </div> | + | </div> |
+ | </div> | ||
+ | <div class="container marin_top"> | ||
+ | <div id="tbox"> | ||
+ | <!-- 这个必须有 id="tbox"--> | ||
+ | <a class="taoba" href="#index_1" title="1"></a> | ||
+ | <a class="taoba" href="#index_2" title="2">Part Table</a> | ||
+ | <!-- <a class="taoba" href="#index_3" title="3">The future plan </a> | ||
+ | <a class="taoba" href="#index_4" title="4">Reference</a> --> | ||
+ | <a id="gotop" href="javascript:void(0)" title="回到顶部">回到顶部</a> | ||
+ | <!-- 这个也是id="gotop" --> | ||
+ | </div> | ||
− | <div class=" | + | <div class="main_context" id="main"> |
− | < | + | <div class="row"> |
− | < | + | <!-- <center> |
− | + | <h2 class="">PREVENTION: GSR FUNCTION</h2> | |
− | + | </center> --> | |
+ | <!-- <div class="mainpage mainpage1"> | ||
+ | <h5 id="index_1">The effects of the CRISPR/Cas9 system on the proliferation, migration and apoptosis in melanoma cells. | ||
+ | </h5> | ||
+ | <h6>Cell proliferation was inhibited by the CRISPR/Cas9 system in melanoma cells.</h6> | ||
+ | <p>The CCK-8 assay was used to investigate the effects of the CRISPR/Cas9 system on cell growth in melanoma cells. Compared with the negative control, cell growth was significantly inhibited in A375 cells (Fig.4A) and G361 cells (Fig.4B) after | ||
+ | treatment of the CRISPR/Cas9 system. </p> | ||
+ | <div class="picture"> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/f/fb/Sfls-demonstrate_fig.1.PNG" width="700" alt="demonstrate_fig.1"> | ||
+ | </div> | ||
+ | <br/><br/> | ||
+ | <h6>Cell migration was suppressed by CRISPR/Cas9 system in melanoma cells. </h6> | ||
+ | <p>The transwell assay was performed to detect the effects of these devices on cell migration. Compared with the NC group, the cell migration rate was obviously lower in the Treatment group both in A375 and G361 cells (Fig 2. A-D). </p> | ||
+ | <div class="picture"> | ||
+ | <img src="https://static.igem.org/mediawiki/2017/3/3c/Sfls-demonstrate_fig.2.PNG" width="700" alt="demonstrate_fig.2"> | ||
+ | </div> | ||
+ | <br/><br/> | ||
+ | <h6>Cell apoptosis was significantly promoted by the CRISPR/Cas9 system in melanoma cells. </h6> | ||
+ | <p>Flow cytometry was performed to detect the effects of the CRISPR/Cas9 system on cell apoptosis. As shown in Fig. 6A-D, compared with the negative control group, cell apoptosis was promoted significantly in A375 and G361 cells in the Treatment | ||
+ | group. The results show that cell apoptosis was inhibited significantly by the synthetic system in melanoma cells. </p> | ||
− | <div class=" | + | <div class="picture"> |
+ | <img src="https://static.igem.org/mediawiki/2017/c/cd/Sfls-demonstrate_fig.3.PNG" width="700" alt="demonstrate_fig.3"> | ||
+ | </div> | ||
+ | <br/><br/> | ||
− | + | </div> | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | </ | + | |
− | |||
− | |||
− | |||
+ | </div> | ||
+ | <br/><br/><br/> --> | ||
− | <div class=" | + | <div class="row"> |
− | |||
− | |||
− | < | + | <div class="mainpage mainpage2"> |
− | + | <h5 id="index_2" style="color:#fc3842">Part Table</h5> | |
− | + | <table id="table"> | |
− | < | + | |
− | < | + | |
− | + | ||
− | + | ||
− | < | + | <tr id="th"> |
− | < | + | <th><b>Name</b></th> |
+ | <th><b>Type</b></th> | ||
+ | <th><b>Description</b></th> | ||
+ | <th><b>Length</b></th> | ||
− | |||
− | < | + | </tr> |
+ | <p> | ||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200000'>BBa_K2200000</a></td> | ||
+ | <td>RNA</td> | ||
+ | <td>Guide RNA (gRNA) is a specific molecule that guides the Cas nuclease to a targeted dsDNA sequence.</td> | ||
+ | <td>20</td> | ||
+ | </tr> | ||
− | </html> | + | <tr > |
− | < | + | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200001'>BBa_K2200001</a></td> |
+ | <td>RNA</td> | ||
+ | <td>gRNA used as a control</td> | ||
+ | <td>20</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200003'>BBa_K2200003</a></td> | ||
+ | <td>Regulatory</td> | ||
+ | <td>Human U6 promoter is a common part for eukaryotic expression systems.</td> | ||
+ | <td>258</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200004'>BBa_K2200004</a></td> | ||
+ | <td>Regulatory</td> | ||
+ | <td>pHEf1A promoter is a common promoter for eukaryotic expression systems.</td> | ||
+ | <td>1174</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200005'>BBa_K2200005</a></td> | ||
+ | <td>Coding</td> | ||
+ | <td>hCas9</td> | ||
+ | <td>4104</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200007'>BBa_K2200007</a></td> | ||
+ | <td>Coding</td> | ||
+ | <td>Gal4 transcription factor is a positive regulator.It's activity can be greatly enhanced by adding th</td> | ||
+ | <td>1233</td> | ||
+ | </tr> | ||
+ | |||
+ | <tr > | ||
+ | <td><a href='http://parts.igem.org/wiki/index.php?title=Part:BBa_K2200008'>BBa_K2200008</a></td> | ||
+ | <td>Regulatory</td> | ||
+ | <td>pHEf1A promoter is a common promoter for eukaryotic expression systems.</td> | ||
+ | <td>1174</td> | ||
+ | </tr> | ||
+ | |||
+ | |||
+ | </p> | ||
+ | </table> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | |||
+ | </div> | ||
+ | <br/><br/><br/> | ||
+ | |||
+ | <!-- <div class="row"> | ||
+ | |||
+ | <div class="mainpage mainpage3"> | ||
+ | <h5 id="index_3">The future plan </h5> | ||
+ | <p>In the future, we would like to verify the system if it can work as expected. Then we would put the regulatory system and CRISPR/Cas9 system together and measure the growth of normal cells and melanoma cells to see whether Cas9 protein only | ||
+ | expresses in melanoma cells. </p> | ||
+ | <p>Next, we will pack the vectors containing the amiRNA, amiRNA binding-site, Cas9 and sgRNA into lentivirus in order to increase the transfection efficiency and use them to deliver the constructs into the target cells in the functional experiments. | ||
+ | </p> | ||
+ | <p>Finally, we also want to sequence the whole genome of the transfected cell and see whether we can reduce the off-target effects on the melanoma cells by the system. </p> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | |||
+ | </div> | ||
+ | <br/><br/><br/> | ||
+ | |||
+ | |||
+ | <div class="row"> | ||
+ | |||
+ | |||
+ | <div class="mainpage mainpage2" id="reference"> | ||
+ | <h5 id="index_4">Reference</h5> | ||
+ | <li>Koo T, Yoon A R, Cho H Y, et al. Selective disruption of an oncogenic mutant allele by CRISPR/Cas9 induces efficient tumor regression[J]. Nucleic Acids Research, 2017.</li> | ||
+ | <li>Huang X, Zhuang C, Zhuang C, et al. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.[J]. Molecular Biosystems, 2017.</li> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | |||
+ | </div>--> | ||
+ | |||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | </div> | ||
+ | |||
+ | <div class="img_bottom_bar container text-center"> | ||
+ | <div class="display-t"> | ||
+ | <div class="display-tc"> | ||
+ | <h1> </h1> | ||
+ | </div> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | <footer id="sfls-footer" role="contentinfo"> | ||
+ | <div class="container"> | ||
+ | <div class="row row-pb-md"> | ||
+ | <div class="col-md-4 sfls-widget"> | ||
+ | <h3><a href="home.html">SFLS.</a></h3> | ||
+ | <p id="ours">Shenzhen Foreign Language School, Yantian Road No.1, Yantian District, Shenzhen, Guangdong, China</p> | ||
+ | </div> | ||
+ | <div class="col-md-2 col-sm-4 col-xs-6 col-md-push-1"> | ||
+ | <ul class="sfls-footer-links"> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Description ">Description</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Design ">Design</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Experiments ">Experiment</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Demonstrate ">Demonstrate</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Collaborations">Collaboration</a></li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="col-md-2 col-sm-4 col-xs-6 col-md-push-1"> | ||
+ | <ul class="sfls-footer-links"> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Basic_Part ">Basic Part</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Composite_Part ">Composite Part</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Model ">Modeling</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/HP/Silver ">HP-Silver</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/HP/Gold_Integrated ">HP-Gold</a></li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | |||
+ | <div class="col-md-2 col-sm-4 col-xs-6 col-md-push-1"> | ||
+ | <ul class="sfls-footer-links"> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Team ">About us</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Attributions ">Attribution</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Engagement">Awards</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Achivement">Achivement</a></li> | ||
+ | <li><a href="https://2017.igem.org/Team:Shenzhen_SFLS/Notebook ">Notebook</a></li> | ||
+ | </ul> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | |||
+ | <div class="row copyright"> | ||
+ | <div class="col-md-12 text-center"> | ||
+ | |||
+ | <p> | ||
+ | <!-- 社会标签 --> | ||
+ | <ul class="sfls-social-icons"> | ||
+ | <li><a href="https://twitter.com/SFLS_iGEM"><img src="https://static.igem.org/mediawiki/2017/6/6c/Sfls_twitter_before.svg" width="30" height="30"></a></li> | ||
+ | <!-- <li><a href="#"><img src="https://static.igem.org/mediawiki/2017/4/40/Sfls_facebook_before.svg" width="30" height="30"></a></li> --> | ||
+ | |||
+ | </ul> | ||
+ | </p> | ||
+ | </div> | ||
+ | </div> | ||
+ | |||
+ | </div> | ||
+ | |||
+ | |||
+ | </footer> | ||
− | |||
− | |||
− | |||
+ | <div class="gototop js-top"> | ||
+ | <a href="javascript:void(0)" class="js-gotop"><i class="icon-arrow-up"></i></a> | ||
+ | </div> | ||
+ | </body> | ||
</html> | </html> |
Revision as of 15:47, 26 October 2017
Part Table
Name | Type | Description | Length |
---|---|---|---|
BBa_K2200000 | RNA | Guide RNA (gRNA) is a specific molecule that guides the Cas nuclease to a targeted dsDNA sequence. | 20 |
BBa_K2200001 | RNA | gRNA used as a control | 20 |
BBa_K2200003 | Regulatory | Human U6 promoter is a common part for eukaryotic expression systems. | 258 |
BBa_K2200004 | Regulatory | pHEf1A promoter is a common promoter for eukaryotic expression systems. | 1174 |
BBa_K2200005 | Coding | hCas9 | 4104 |
BBa_K2200007 | Coding | Gal4 transcription factor is a positive regulator.It's activity can be greatly enhanced by adding th | 1233 |
BBa_K2200008 | Regulatory | pHEf1A promoter is a common promoter for eukaryotic expression systems. | 1174 |